

PUBLICATIONS:

Book chapters

Furger P. Médecine Interne: du symptôme au diagnostic. Transcontinental Metrolitho, 2005, First edition.

Dermatology chapter. pp 497-508

Furger Dermatology P. Guide médical: Urgences et Diagnostic différentiel. Transcontinental Metrolitho, 2003, First edition.

Dermatology chapter.

Peer-reviewed articles: 136 publications as of October 2015

- 136 : Garbe C, Basset-Seguín N, **Poulin Y**, Larsson T, Østerdal ML, Venkata R, Lear JT. Efficacy and safety of follow-up field treatment of actini keratosis with ingenol mebutate 0.015% gel: a randomised controlled 12-month study. *Br J Dermatol*. 2015 Oct 15. doi: 10.1111/bjd.14222. [Epub ahead of print] PubMed PMID: 26471889.
- 135 : Paul C, Cather J, Gooderham M, **Poulin Y**, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). *Br J Dermatol*. 2015 Sep 10. doi: 10.1111/bjd.14164. [Epub ahead of print]. PubMed PMID: 26357944.
- 134 : McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpfu S; FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. PubMed PMID: 26135703.
- 133 : Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. PubMed PMID: 26072109.
- 132: Guenther LC, Barber K, Searles GE, Lynde CW, Janiszewski P, Ashkenas J; Canadian Non-melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 1: Introduction to the Guidelines. *J Cutan Med Surg*. 2015 May;19(3):205-15. doi: 10.1177/1203475415588652. Epub 2015 May 27. PubMed PMID: 26016676.
- 131: Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, **Poulin Y**, Cohen AD, Goyal K, Fakhrazadeh S, Calabro S, Chevrier M, Langhoff W, You Y, Leonardi CL. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). *JAMA Dermatol* 2015 Sep 1;151(9):961-9.
- 130: Bourcier M, Papp KA, Gulliver WP, **Poulin Y**, Barber K, Poulin-Costello M, Shelton J. Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series. *J Cutan Med Surg*. 2015 May 7. pii:1203475415584511. [Epub ahead of print] PubMed PMID: 25951825.
- 129 : Zloty D, Guenther LC, Sapijaszko M, Barber K, Claveau J, Adamek T, Ashkenas J; Canadian Non-melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma. *J Cutan Med Surg*. 2015 May-Jun;19(3):239-48.
- 128: **Poulin Y**, Lynde CW, Barber K, Vender R, Claveau J, Bourcier M, Ashkenas J; Canadian non-Melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses. *J Cutan Med Surg*. 2015 May;19(3):227-38. doi: 10.1177/1203475415583414. Epub 2015 Apr 29. PubMed PMID: 25926621.
- 127: Sapijaszko M, Zloty D, Bourcier M, **Poulin Y**, Janiszewski P, Ashkenas J; Canadian Non-melanoma Skin Cancer Guidelines Committee. Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma. *J Cutan Med Surg*. 2015 May;19(3):249-59. doi: 10.1177/1203475415582318. Epub 2015 Apr 28. PubMed PMID: 25922470.
- 126: Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunyetz RA, **Poulin Y**, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. *Exp Dermatol*. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8. PubMed PMID: 28362.
125. Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaquadah P, **Poulin Y**, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial. *Pediatrics*. 2015 Mar 23. pii: peds.2014-1990. [Epub ahead of print] PubMed PMID: 25802354.
124. Gulliver W, Lynde C, Dutz JP, Vender RB, Yeung J, Bourcier M, Dion PL, Hong CH, Searles G, **Poulin Y**. Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis. *J Cutan Med Surg*. 2015 Jan;19(1):22-7. doi: 10.2310/7750.2014.13151. Epub 2015 Jan 1. PubMed PMID: 25775659.
123. Tan J, Frey MP, Knezevic S, **Poulin Y**, Lynde CW, Gulliver WP, Gupta AK, SebaldtRJ, Thomas DR, Sapra S. The Relationship Between Dermatologist- and Patient-Reported Acne Severity Measures and Treatment Recommendations. *J Cutan Med Surg*. 2015 Mar 11. pii: 1203475415576464. [Epub ahead of print] PubMed PMID: 25775621.
122. Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, **Poulin Y**, Shelton J, Garces K, Toole J, Poulin-Costello M. Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE. *J Eur Acad Dermatol Venereol*. 2015 Jan 21. doi: 10.1111/jdv.12934. Epub ahead of print] PubMed PMID:25611084.
121. Stein Gold L, Kirck L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. *J Drugs Dermatol*. 2014 Nov;13(11):1380-6. PubMed PMID: 25607706.
120. Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, **Poulin Y**, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. *Br J Dermatol*. 2014 Oct 11. doi: 10.1111/bjd.13469. [Epub ahead of print] PubMed PMID: 25307931.

119. Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis. (FEATURE). *Br J Dermatol*. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11. PubMed PMID: 25132411.
118. Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; The PHOENIX 2 Investigators. Long-term efficacy and safety of Ustekinumab, with and without dosing adjustment in patients with moderate-to-severe psoriasis : Results from the PHOENIX 2 study through 5 years of followrcier-up. *Br J Dermatol* 2014 Oct 11.
117. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, **Tyring S**, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; **ERASURE Study Group; FIXTURE Study Group**. Secukinumab in plaque psoriasis--results of two phase 3 trials. *N Engl J Med*. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. PubMed PMID: 25007392
116. Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde C, Poulin Y, Shelton J, Toole J, Vieira A, Poulin-Costello M. A randomized, blinded assessor study to Evaluate the Efficacy and Safety of Etanercept 50 mg once weekly plus as Needed topical agents vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). *J Eur Acad Dermatol Venereol* 2014 Jul 1.
115. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; **ERASURE Study Group; FIXTURE Study Group**. Secukinumab in plaque psoriasis--results of two phase 3 trials. *N Engl J Med*. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. PubMed PMID: 25007392
114. Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, **Poulin Y**, Shelton J, Toole J, Vieira A, Poulin-Costello M. A Randomized, blinded assessor study to Evaluate the efficacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). *J Eur Acad Dermatol Venereol*. 2014 Jul 1.Epub ahead of print.
113. Navarini AA, **Poulin Y**, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. *J Drugs Dermatol*. 2014 May;13(5):554-62.
112. Lynde CW, **Poulin Y**, Vender R, Bourcier M, Khalil S. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. *J Am Acad Dermatol* 2014, March 18, Epub ahead of print.
111. Wylomanski S, Bouquin R, Philippe HJ, **Poulin Y**, Hanf M, Dreno B, Rouzier R, Quéreux G. Psychometric properties of the French Female Sexual Function Index (FSFI). *Qual Life Res* 2014 March 2. Epub ahead of print.
110. **Poulin Y**, Sheth P, Gu Y, Teixeira HD. Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal Of Adalimumab Therapy. *Dermatol Research* 2014 March 2. Epub ahead of print.
109. Strober BE, **Poulin Y**, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in C-reactive protein in patients with moderate-to-severe Psoriasis switched to adalimumab therapy after sub-optimal response to Etanercept, Methotrexate or Phototherapy. *J Eur Acad Dermatol Venereol* 2014 Jan 15. Epub ahead of print
108. Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, Kerkmann U, Ghislain PD, **Poulin Y** ; The PHOENIX 1 Investigators. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. *Br J Dermatol* 2013 Sept 30. Doi: 10.1111/bjd.12632 (Epub ahead of print).
107. Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, **Poulin Y**, Ho V, Guenther L, Kunyetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P. Immune response to Pneumococcus and Tetanus Toxoid in patients with moderate-to-severe psoriasis following Long-term ustekinumab use. *J Drugs Dermatol* 2013 Oct 1;12 (10): 1122-9.
106. **Poulin Y**, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC. Efficacy of adalimumab across subgroups of patients With moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH. *J Eur Acad Dermatol Venereol* 2013 Jun 22. Doi: 10.1111/jdv.12198 (Epub ahead of print)
105. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Titchlin C, Brodmerkel C, Li S, Wang Y, Mendelson AM, Doyle MK; **PSUMMIT 1 study group**. Efficacy and safety of Ustekinumab in patients with active psoriatic arthritis: 1 year results of the Phase 3 multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet* 2013 Aug 31;382(9894):780-9
104. Papp K, **Poulin Y** , Vieira A Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. *J Cutan Med Surg*. 2013 Mar-Apr;17(2):89-105.
103. Papp K, Poulin Y, Vieira A, Shelton J, Polin-Costello M. Disease characteristics in patients with and without psoriatic arthritis treated with etanercept. *J Eur Acad Dermatol Venereol* 2013, March 7;
102. **Poulin Y** , Wasel N., Chan D, Bernstein G, Andrew R, Fraquelli E, Papp K. Evaluating practice patterns for managing moderate to severe psoriasis: Role of the family physician. *Can Fam Physician*. July 2012;58(7) :e390-400
101. Tan J, O'Toole A, Zhang X, Dreno B, **Poulin Y**. Evaluation of the French version of the 4-item index of the Acne-QoL (AcneQ4fr) *Qual Life Res*. 2012 Apr 28. [Epub ahead of print]
100. Papp K, Menter A, **Poulin Y**, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study, *J Eur Acad Dermatol Venereol*. 2012 Mar 16.doi: 10.1111/j.1468-3083.2012.04515.x. [Epub ahead of print]
99. Albrecht L, Bourcier M, Ashkenas J, Papp K; Canadian Psoriasis Guidelines Committee. Topical psoriasis therapy in the age of Biologics: evidence-based treatment recommendations. *J Cutan Med Surg*. 2011 Nov-Dec;15(6):309-21
98. Bissonnette R, **Poulin Y**, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy and safety of topical WBI-1001 in Patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. *Br J Dermatol* 2012 Apr;166:853-60.
97. Papp K, **Poulin Y**, Barber K, Lynde C, Prinz JC, Berg M, Kerrouche N, Rives VP. Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis. *J Eur Acad Dermatol Venereol* 2012 Nov;26 911): 1407-14.
96. Tan J, O'Toole A, Zhang X, Dreno B, **Poulin Y**. Cultural and linguistic validation of acne-QoL in French. *J Eur Acad Dermatol Venereol* 2011 Jul 29. Doi: 10.1111/j. 1468-3083.2011.04193.x. (Epub ahead of print)

95. Lynde CW, Gupta A, Guenther L, **Poulin Y**, Levesque A, Bissonnette R. A Randomized study comparing the combination of nbUVB and Etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of Etanercept. *J Dermatol Treat* 2011 Jul 29 (Epub ahead of print)
94. Papp K, Gulliver W, Lynde C, **Poulin Y**, Ashkenas For The Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the management of plaque psoriasis: overview. *J Cut Med Surg* 2011 Jul-Aug; 15 (4):210-219
93. Gordon K, Papp K, **Poulin Y**, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe Psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. *J Am Acad Dermatol* 2011 Jul 11 (Epub ahead of print)
92. Guenther L, Han C, Szapary P, Schenkel B, **Poulin Y**, Bourcier M, Ortonne JP, Sofen H. Impact of Ustekinumab on health-related Quality of Life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. *J Eur Acad Dermatol Venereol* 2011 Apr 27 (Epub ahead of print)
91. **Poulin Y**, Sanchez NP, Bucko A, Fowler J, Jarrat M, Kempers S, Kerrouche N, Dhuin JC, Kunyetz R. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among severe acne vulgaris patients: results of a randomized controlled trial. *Br J Dermatol* 2011 April 1 (Epub ahead of print)
90. Feldman SR, Tan J, **Poulin Y**, Dirschka T, Kerrouche N, Manna V. The efficacy of adapalene-benzoyl peroxide combination Increases with number of acne lesions. *J Am Acad Dermatol* 2011 March 23 (Epub ahead of print)
89. Strober BE, **Poulin Y**, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. *J Am Acad Dermatol* 2011; Apr, 64 (4) 671-681.
88. Bissonnette R, **Poulin Y**, Guenther L, Lynde C, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab : a randomized, double-blind placebo-controlled study. *J Eur Acad Dermatol Venereol* 2011 Feb 23 (Epub ahead of print)
87. **Poulin Y**, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, Chan D. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. *Int J Dermatol* 2010 Dec;49(12) 1368-1375
86. Lynde C, Guenther L, Diepgen TL, Sasseville D, **Poulin Y**, Gulliver W, Agner T, Barber K, Bissonnette R, Ho V, Shear NH, Toole J. Canadian hand dermatitis management guidelines. *J Cut Med Surg* 2010 Nov-Dec;14(6):267-284
85. Papp KA, **Poulin Y**, Bissonnette R, Bourcier M, Toyh D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. *J Am Acad Dermatol* 2010 Sep 16 (Epub ahead of print).
84. Tan JK, Tang J, Fung K, Gupta AK, Thomas RD, Sapra S, Lynde C, **Poulin Y**, Gulliver W, Sebaldt RJ. Development and validation of a scale for acne scar severity (SCAR-S) of the face and trunk. *J Cut Med Surg* 2010 Jul-Aug; 14 (94): 156-160
83. Papp K, Valenzuela F, **Poulin Y**, Bernstein G, Wasel N. Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population. *J Cut Med Surg*. Jul-Aug 2010;14(4):167-174
82. Hordinsky M, Fleischer A, Rivers JK, **Poulin Y**, Belsito D, Hulstsch T. Efficacy and Safety of Pimecrolimus Cream 1% in Mild-to-Moderate Hand Dermatitis: Double-Blind Trial. *Dermatology* 2010;221(1):71-77
- 81.- CANADIAN PSORIASIS GUIDELINES. CDA Website: WWW.DERMATOLOGY.CA Official publication to come.
80. Bissonnette R, Bolduc C, **Poulin Y**, Guenther L, Lynde CW, Maari C. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. *J Am Acad Dermatol*. 2010, May 20. .
79. **Poulin Y**, Thérien G. Drug-Induced Hepatitis and Lupus during Infliximab Treatment for Psoriasis : Case Report and Literature Review. *J Cut Med Surg* 2010 Mar-Apr; 14(2):100-104.
78. Aubert J, Reiniche P, Fogel P, **Poulin Y**, Lui H, Lynde C, Shapiro J, Villemagne H, Soto P, Voegel JJ. Gene expression profiling in psoriatic scalp hair follicles : clobetasol propionate shampoo 0,05% normalizes psoriasis disease markers. *J Eur Acad Dermatol Venereol* 2010 Mar 23. Epub ahead of print.
77. Wexler D, Searles G, Landells I, Shear NH, Bissonnette R, Papp K, **Poulin Y**, Langley R, Gulliver WP. Update on Alefacept safety. *J Cut Med Surg*. 2009. Dec;13 Suppl 3: S139-147
76. **Poulin Y**, Papp K, Bissonnette R, Barber K, Kerrouche N, Villemagne H. Clobetasol Propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. *J Derm Treatment* 2010 Feb 4
75. **Poulin Y**, Papp K, Bissonnette R, Guenther L, Tan J, Kerrouche N, Villemagne H; CalePso Study Team. Clobetasol Propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. *Cutis* 2010 Jan;85(1):43-50
74. Wasel N, **Poulin Y**, Andrew R, Chan D, Fraquelli E, Papp K. A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients. *J Cutan Med Surg*. 2009;13(6):294-302.
73. **Poulin Y**, Bourcier M. Practical aspects of prescribing a biologic. *J Cutan Med Surg*. 2009;13 Suppl 2:S93-S101.
72. **Poulin Y**, Langley RG, Teixeira HD, Martel MJ, Cheung S. Biologics in the treatment of psoriasis: clinical and economic overview. *J Cutan Med Surg*. 2009 Sep-Oct;13 Suppl 2:S49-57.
71. Lynde CW, **Poulin Y**, Guenther L, Jackson C. The Burden of Psoriasis in Canada: Insights from the pSoriasis Knowledge IN Canada (SKIN) Survey. *J Cutan Med Surg*. 2009 Sep-Oct;13(5):235-52.
70. Gold LS, Tan J, Cruz-Santana A, Papp K, **Poulin Y**, Schlessinger J, Gidner J, Liu Y, Graeber M; Adapalene-BPO Study Group. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. *Cutis*. 2009 Aug;84(2):110-6.
69. **Poulin Y**. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. *J Cut Med Surg*. 2009 Jul-Aug;13(4):221-5
68. Tan JK, Balagurusamy M, Fung K, Gupta AK, Richard Thomas D, Sapra S, Lynde C, **Poulin Y**, Gulliver W, Sebaldt RJ. Effect of quality of life impact and clinical severity on adherence to topical acne treatment. *J Cutan Med Surg*. 2009 Jul-Aug;13(4):204-8
67. Chan B, Hales B, Shear N, Ho V, Lynde C, **Poulin Y**, Mittmann N. Work-related lost productivity and its economic impact on canadian patients with moderate to severe psoriasis. *J Cutan Med Surg*. 2009 Jul-Aug;13(4):192-7
66. Tan J, Thomas R, Wang B, Gratton D, Vender R, Kerrouche N, Villemagne H; CalePso Study Team. Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis. *Cutis*. 2009 Mar;83(3):157-64
65. Bissonnette R, **Poulin Y**, Bolduc C, Maari C, Provost N, Syrotuik J, Poulin-Costello CM, Nigen S. Etanercept in the treatment of palmoplantar pustulosis. *J Drugs Dermatol*. Oct 2008; 7 (10) 940-946

64. Tan JK, Li Y, Fung K, Gupta AK, Thomas DR, Sapra S, Lynde C, **Poulin Y**, Gulliver W, Sebaldt RJ. Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. *J Cutan Med Surg*. 2008 Sep-Oct;12 (5):235-42
63. Jemec BGE, Ganslandt C, Ortonne JP, **Poulin Y**, Burden AD, Unamuno P, Berne B, Figueiredo A, Austad J. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. *J Am Acad Dermatol*. Sept 2008;59: 455-463
62. Tan JKL, Tang J, Fung K, Gupta AK, Thomas D R, Sapra S, Lynde C, **Poulin Y**, Gulliver W, Sebaldt RJ. Prevalence and Severity of Facial and Truncal Acne in a Referral Cohort. *J Drugs in Derm*, June 2008, vol 7 (6):553-6
61. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 Monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*. 2008 May 17;371(9625):1675-84.
60. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*. 2008 May 17;371(9625):1665-74.
59. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). *Br J Dermatol*. 2008 Mar;158(3):558-66.
58. **Poulin Y**, Bissonnette R, Juneau C, Cantin K, Drouin R, Poubelle PE. XP-828L in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study. *Altern Med Rev*. 2007 Dec;12(4):352-9
57. Tan JK, Tang J, Fung K, Gupta AK, Thomas DR, Sapra S, Lynde C, **Poulin Y**, Gulliver W, Sebaldt RJ. Development and validation of a comprehensive acne severity scale. *J Cutan Med Surg*. 2007 Nov-Dec;11(6):211-216.
56. Tan JK, Thomas DR, **Poulin Y**, Maddin F, Tang J. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. *J Cutan Med Surg*. 2007 Nov-Dec;11(6):195-201.
55. **Poulin Y**. Efalizumab for moderate to severe plaque psoriasis: A Clinical Review. HELIX review Series. Issue 2, 2007.
54. Gupta AK, Lynde CW, **Poulin Y**, Smith K, Lewis R, Zip C. Position Statement for Isotretinoin. *J Cut Med Surg* 2007 May-Jun ;11; 123-124.
53. Tyring S, Gordon KB, **Poulin Y**, Langley RG, Gottlieb AB, Dunn M, Jarheis A. Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients with Psoriasis. *Arch Dermatol*. June 2007;143: 719-726
52. **Poulin Y**, Gupta AK, Amiss JD. Efficacy of Etanercept in the Management of Plaque Psoriasis and Psoriatic Arthritis. *J Cut Med Surg*. April 2007;11.S1: S14 - S22.
51. Draelos ZD, Carter E, Maloney M, Elewski B, **Poulin Y**, Lynde C, Garrett S. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% fo the treatment of acne vulgaris. *J Am Acad Dermatol*. March 2007; 56: 439-447.
50. Vender RB, Lynde CW, **Poulin Y**. Prevalence and epidemiology of onychomycosis. *J Cutan Med Surg*. 2006 Dec;10 Suppl 2:S28-33
49. Gupta AK, **Poulin Y**, Lynde CW. Canadian perspectives on antifungal treatment for onychomycosis. *J Cutan Med Surg*. 2006 Dec;10 Suppl 2:S34-8.
48. **Poulin Y**, Thomas R, Gupta AK. Brief treatment guide for onychomycosis. *J Cutan Med Surg*. 2006 Dec;10 Suppl 2:S39-43
47. **Poulin Y**, Bissonnette R, Juneau C, Cantin K, Drouin R, Poubelle PE. XP-828L in the Treatment of Mild to Moderate Psoriasis: Randomized, Double-Blind, Placebo-Controlled Study. *J Cutan Med Surg*. 2006 Sep-Oct;10(5):241-8.
46. **Poulin Y**, Papp KA, Carey W, Gulliver W, Gupta AK. A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence. *J Cutan Med Surg*. 2006 Apr 20.
45. Langley RG, Ho V, Lynde C, Papp KA, **Poulin Y**, Shear N, Toole J, Zip C. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. *J Cutan Med Surg*. 2006 Apr 20
44. Papp KA, Ho V, Langley R, Lynde C, **Poulin Y**, Shear N, Toole J, Zip C. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. *J Cutan Med Surg*. 2006 Apr 20
43. Bissonnette R, Papp K, **Poulin Y**, Lauzon G, Aspeslet L, Huizinga R, Mayo P, Foster RT, Yatscoff RW, Maksymowych WP; ISA247 Psoriasis Study Group. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. *J Am Acad Dermatol*. 2006 Mar;54(3):472-8.
42. Kaufmann R, Bieber T, Helgesen AL, Andersen BL, Luger T, **Poulin Y**, Al-Hafidh J, Paul C; the multicentre investigator group. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. *Allergy*. 2006 Mar;61(3):375-81.
41. Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH Jr, Kanof NB, Kempers SE, Maddin S, **Poulin YP**, Wilson DC, Hwa J, Liu Y, Graeber M; Adapalene Study Group. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. *J Am Acad Dermatol*. 2006 Feb;54(2):242-50.
40. **Poulin Y**, Pouliot Y, Lamiot E, Aattouri N, Gauthier SF. Safety and efficacy of a milk-derived extract in the treatment of plaque psoriasis: an open-label study. *J Cutan Med Surg*. 2005 Dec;9(6):271-5.
39. Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, **Poulin Y**, Zip C. Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. *J Cutan Med Surg*. Sept-Oct 2005;8: 321-337.
38. **Poulin Y**. Practical Approach to the Hormonal Treatment of Acne. *J Cut Med Surg*. 2005 Mar 31.
37. Langley R, Gupta AK, **Poulin Y**, Guenther L, Barber K, Gulliver W, Lynde C. The Use of Alefacept in the Treatment of Psoriasis. *J Cut Med Surg*. August 2004;8: S14-S18.

36. Lui H, Langley R, **Poulin Y**, Gupta AK, Carey W, Guenther L, Searles G, Toole J, Lnde C, Gulliver W, Barber K. Incorporating Biologics into the Treatment of Psoriasis. *J Cut Med Surg.* August 2004;8: S8-S13
35. Gupta AK, Langley R, **Poulin Y**, Lui H, Searles G, Carey W, Toole J, Inniss K. Pathogenesis of Psoriasis and Current Challenges. *J Cut Med Surg.* August 2004;8: S3-S7
34. **Poulin Y**. Psoriasis Today: A new Paradigm. *J Cut Med Surg.* August 2004;8: S1-S2
33. Lowe N, Gifford M, Tanghetti E, **Poulin Y**, Goldman M, Tse Y, Yamauchi P, Rosenzweig H, Kang S. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. *J Cosmet Laser Ther.* 2004;6(2):79-85.
32. Jarrat M, Breneman D, Gottlieb AB, **Poulin Y**, Liu Y, Foley V: Clobetasol Propionate Shampoo 0.05%: A new option to treat Patients with Moderate to Severe Scalp Psoriasis. *J Drugs Dermatol* July/August 2004; 3 (4): 367-373.
31. Lowe NJ, Gifford M, Tanghetti E, **Poulin YP**, Goldman M, Tse Y, Yamauchi P, Rosenzweig H, Kang S. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. *J Cosmet Laser Ther.* 2004;6:79-85
30. Tan J, Langley R for the Canadian Open-label multicentre Study. Safety and Efficacy of Tacrolimus ointment 0.1% in atopic dermatitis-a Canadian open-label Multicentre study. Submitted for publication 9march 2004.
29. Tan J, Thomas R, Sapra S, **Poulin Y**, Lynde C, Gulliver W, Sebaldt R. Baseline demographics: interim analysis of Canadian Acne Epidemiological Survey. *JEADV*2003;17(suppl 3):145(abstract).
28. Tan J, Thomas R, Sapra S, **Poulin Y**, Lynde C, Gulliver W, Sebaldt R. An epidemiological and outcomes survey of Canadian Acne Patients. *JEADV*2003;17(suppl 3):113
27. Nigen S, **Poulin Y**, Rochette L, Levesque MH. Pyodermitis-Pyostomatitis Vegetans : Two Cases and Review of the literature. *J Cut Med Surg* 2003; 7: 250-255.
26. Dupéré, A. , **Poulin, Y** : Facial lipoatrophy following systemic lupus erythematosus. *J Cut Med Surg* 2003; 7: 232-235.
25. Dessureault J, **Poulin Y**, Bourcier M, Gagne E. Olmsted Syndrome- Palmoplantar and Periorificial Keratodermas: Association with Malignant Melanoma. *J Cut Med Surg* 2003; 7: 236-242.
24. Lemay A, **Poulin Y**. Oral contraceptives as anti-androgenic treatment of acne. *J.Obstet Gynaecol Can.* 2002 Jul;24(7):559-67
23. **Poulin Y**: Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): A new formulation for the treatment of psoriasis. *Skin Therapy Lett.* 2002 Jun;7(6):1-3
22. Webster G, Guenther L, **Poulin Y**, Solomon B, Loven K, Lee J. Assessing the Cost-Effectiveness of Tazarotene 0.1% Gel Versus Adapalene 0.1% Gel in Patients with Facial Acne Vulgaris. *Clinical Therapeutics.* July 2002.
21. **Poulin Y**. Psoriasis: Current Therapy. *J Cutan Med Surg.* 2002 May-Jun; 6 (3 Suppl)
20. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, **Poulin Y**. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. *Br J Dermatol.* 2002 Jan;146(1):94-100.
19. Webster GF, Guenther L, **Poulin YP**, Solomon B, Loven K: A Multicenter, Double-Blind, Randomized Comparison of the Efficacy and Tolerability of Treating Facial Acne Vulgaris Once Daily with Tazarotene 0.1% gel or Adapalene 0.1% gel. *CUTIS.* Feb 2002; 69: 4-11.
18. Tan JK, Girard C, Krol A, Murray HE, Papp KA, **Poulin Y**, Chin DA, Jeandupeux D. Randomized Placebo-controlled Trial of Metronidazole 1% Cream with Sunscreen SPF 15 in Treatment of Rosacea. *J Cutan Med Surg.* 2002 May 13:
17. Douglas W.S. , **Poulin Y.** , Decroix J. , Ortonne J.P. , Mrowietz U. , Gulliver W. , Krogstad A.L. , Larsen L., Iglesias S F.G. , Buckley C. ,Bibby A.J. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. *Acta Dermato-Venereologica* vol. 82, No 2, 2002: 131-135
16. **Poulin, Y**, Guenther, L , Pariser, DM: A Comparison of Tazarotene 0.1 % Gel Once Daily plus Mometasone Furoate 0.1 % Cream Once Daily Versus Calcipotriene 0.005 % Ointment Twice Daily in the Treatment of Plaque Psoriasis. *Clin Ther.* 2000 Oct; 22 (10): 1225 – 1238
15. Lemay, A, **Poulin, Y**: Hyperandrogenism: Objective clinical Evaluation of Dermatological Manifestations. *SOGC Journal.*
14. Alain J., **Poulin Y.**, Cloutier R., Gagné, E., Baril, J.. Calciphylaxis: Seven New Cases. *Journal of Cutaneous Medicine and Surgery* 2000 Oct; 4 (4): 213 – 218.
13. Maddin, WS, Landells, IDR., **Poulin, Y**, Searles G., Smith, Kevin C., Tan, JKL, Toole, J, Zip, C, Degreef, H: Treatment of Acne Vulgaris and Prevention of Acne Scarring: Canadian Consensus Guidelines. *J Cut Med Surg.* Vol. 4, Suppl. 1, June 2000, pp S4-1 - S4-13
12. **Poulin, Y**. Tazarotene 0.1 % gel in combination with Mometasone furoate cream in plaque Psoriasis: a photographic tracking study. *CUTIS.* January 1999; 63: 41 - 48.
11. Lebwohl, M, **Poulin, Y**: Tazarotene in combination with topical corticosteroids. *J. Am. Acad. Dermatol.* October 1998; 39-. S139 - S143
10. **Poulin, Y**.: Balanites et balanoposthites. *Le Médecin du Québec.* August 1998, vol.33-.pp.34-39
09. **Poulin, Y**.: Tazarotene plus Steroid effective Psoriasis Treatment. *The Chronicle of Skin & Allergy.* February 1998, pp 17-18.
08. **Poulin, Y**.: Le syndrome de la Rosacée. *Actualité Médicale* vol. 1 8 no.24, 25 juin 1997, pp.20-22
07. **Poulin Y**., : Piqûres et morsures d'insectes: diagnostic et traitement. *Médecine sport. Actualité médicale,* vol.17 no.20, 22mai 1996,pp7-8.
06. **Poulin Y**.: Callosités, cors et verrues plantaires-. diagnostic et traitement. *Médecine sport. Actualité médicale,* octobre 1993, p.p. 14-15
05. **Poulin Y**., Pery H.O., Muller S.A.: Pemphigus Vulgaris: Results of treatment with gold as a steroid-sparing agent in a series of thirteen patients. *J. Am. Acad. Dermatol* 11 : 851-857, Nov. 1984
04. **Poulin Y**., Pery H.O., Muller S.A.-. The Olmsted syndrome- Palmo-plantar and Periorificial Keratoderma. *J. Am. Acad. Dermatol* 4: 600-610, 1984.
03. **Poulin Y**., Girard C. Epidermolysis Bullosa Acquisita. *Can. Derm. Ass. Bull.* Vol. 1 no. 20, June. 1983.
02. **Poulin Y**., Bellefeuille J.: Les anti-histaminiques de type bloqueurs H 1. *Un. Med. Can.* 112: 78-79, Jan. 1983.
01. Shapcott D, Fisch C., **Poulin Y**.: Pitfalls in the use of serum iron concentration in diagnosis of anaemia. *Clin. Chem.* June 1980;7: 1104-105.